Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Parabilis Medicines, Inc. before investing.

In this article, we go over a few key elements for understanding Parabilis Medicines, Inc.’s stock price such as:

• Parabilis Medicines, Inc.’s current stock price and volume
• Why Parabilis Medicines, Inc.’s stock price changed recently
• Upgrades and downgrades for PBLS from analysts
• PBLS’s stock price momentum as measured by its relative strength

About Parabilis Medicines, Inc. (PBLS)

Before we jump into Parabilis Medicines, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Want to learn more about Parabilis Medicines, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Parabilis Medicines, Inc..

Parabilis Medicines, Inc.’s Stock Price as of Market Close

As of August 20, 2026, 4:00 PM, CST, Parabilis Medicines, Inc.’s stock price was $39.580.

Parabilis Medicines, Inc. is down 4.21% from its previous closing price of $41.320.

During the last market session, Parabilis Medicines, Inc.’s stock traded between $39.310 and $41.490. Currently, there are approximately 28.91 million shares outstanding for Parabilis Medicines, Inc..

Parabilis Medicines, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Parabilis Medicines, Inc. Stock Price History

Parabilis Medicines, Inc.’s (PBLS) price is currently up 16.48% so far this month.

During the month of August, Parabilis Medicines, Inc.’s stock price has reached a high of $41.490 and a low of $32.090.

Over the last year, Parabilis Medicines, Inc. has hit prices as high as $41.490 and as low as $24.510.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Parabilis Medicines, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 20, 2026, there were analysts who downgraded Parabilis Medicines, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Parabilis Medicines, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Parabilis Medicines, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Parabilis Medicines, Inc. (PBLS) by visiting AAII Stock Evaluator.

Relative Price Strength of Parabilis Medicines, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 20, 2026, Parabilis Medicines, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Parabilis Medicines, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Parabilis Medicines, Inc. Stock Price: Bottom Line

As of August 20, 2026, Parabilis Medicines, Inc.’s stock price is $39.580, which is down 4.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Parabilis Medicines, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.